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ABSTRACT 
Introduction: [18F]FMISO, the widely used positron emission tomography (PET) hypoxia tracer, is a chiral 
compound clinically used as a racemic mixture.  The purpose of this study was to synthesize the 
individual (R)- and the (S)- enantiomers of [18F]FMISO and compare their PET imaging characteristics.  
Methods: The radiosynthesis of enantiopure (R)- and (S[18F]FMISO was based on Co(salen) (N,N'-bis(3,5-
di-tert-butylsalicylidene)-1,2-cyclohexanediaminocobalt)-mediated opening of enantiopure epoxides 
with [18F]HF. The uptake and clearance of the individual [18F]FMISO antipodes were investigated using 
micro-PET/CT imaging performed on mice bearing FaDu tumors. Image-derived biodistribution was 
obtained from micro-PET/CT scans performed at 1 and 3 hours post injection (p.i.). In addition, the 
uptake patterns of each enantiomer were observed using two-hour dynamic micro-PET/CT scans and 
the time-activity curves from different organs were compared.  
Results: The individual (R)- and (S)-[18F]FMISO enantiomers were synthesized in one step with high 
enantiomeric excess (ee) > 99% and radiochemical purity > 97% using custom-made automation 
module. The dynamic micro-PET/CT scanning revealed a faster initial uptake of the (R)-[18F]FMISO 
enantiomer in tumor and muscle tissues, however the difference became progressively smaller with 
time. The tumor-to-muscle (T/M) and tumor-to-liver (T/L) ratios remained nearly identical for the (R)- 
and (S)-forms at all time points. The micro-PET/CT imaging at 1 and 3 hours p.i. did not show any 
significant enantioselective tissue uptake. 
Conclusions: Although the (R)-enantiomer of [18F]FMISO demonstrated a somewhat faster initial tumor 
and muscle uptake no significant enantioselective tissue uptake was observed at later time points. The 
T/M- and T/L- ratios for the (R)- and (S)-forms were the same within the experimental error at all times. 
Therefore, the use of enantiopure [18F]FMISO is unlikely to present any practical clinical benefit for PET 
imaging. 
 
1. Introduction 
Inefficient angiogenesis during growth of solid tumors often leads to spatial and temporal deficiency in 
their oxygen supply. When the partial pressure of oxygen decreases significantly a condition of oxygen 
starvation, or hypoxia, occurs. Tumor cells respond to hypoxia by activating several isoforms of hypoxia 
inducible factor HIF [1], which, together with various microRNAs [2]  regulate gene expression 
responsible for glycolysis, apoptosis, DNA repair, and angiogenesis in tumor cells. As a consequence, 
hypoxia increases tumor cell invasion [3], activates autophagy [4] and promotes tumor motility [5] and 
cell pluripotency [6]. Importantly, hypoxia often increases resistance of cancer cells to chemotherapy 
and radiotherapy [7]. In clinical settings, the determination of hypoxia status could provide important 
information to stratify patients to optimize treatment, including hypoxic radiosensitizers and hypoxia 
guided radiation therapy. Presently, a number of methods for detection and measuring tumor hypoxia 
are available, such as the Eppendorf needle electrode, immunostaining, fluorescence and diffuse 
reflectance spectroscopy [8]. In the 1980s, positron emission tomography (PET) emerged as a non-
invasive, viable-cell specific, highly sensitive quantitative hypoxia accessing modality. Subsequently, a 
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series of 2-nitro-imidazoles labeled with fluorine-18 in a position peripheral to the imidazole ring was 
developed and successfully used to measure hypoxia [9]. Among these, ([18F]1-(2-nitroimidazole-1-yl)-3-
fluoropropane-2-ol ([18F]FMISO) is currently the most used hypoxia PET tracer (Fig. 1).   
Central to the structure-activity relationship of [18F]FMISO is  a redox-active 2-nitroimidazole ring, which 
allows the molecule to accept terminal electrons from the respiratory cycle. In hypoxic regions, where 
the concentration of dioxygen is too low to re-oxidize the initially formed –NO2·–, the anion radical 
undergoes further reduction to –NH2, and the resulting species binds covalently to the macromolecules. 
 
[18F]FMISO is a chiral compound, which is currently used as a racemic mixture in PET. It is well known 
that chirality may affect the affinity and/or efficacy of drugs [10], and different enantiomers may display 
different pharmacokinetic profiles [11]. Several factors may cause such differences. In particular, binding 
to tissue and plasma proteins, primarily to albumin, as well as to lipoproteins and red blood cells can be 
stereoselective [11,12]. As this binding affects the plasma concentration of free drug, this could in turn 
affect the rates of excretion and degradation and ultimately plasma half-life and biodistribution. In 
addition, active renal excretion and reabsorption, as well as enzymatic drug metabolism [11] have been 
shown to be stereoselective in certain cases [11,13]. Therefore, it is generally important to determine if 
different enantiomers of a drug have different in vivo efficacy based on stereoselective 
pharmacokinetics. Further, in the special case of [18F]FMISO, the electron transport  to the 2-
nitroimidazole ring can be mediated by a variety of chiral macromolecules, including nitroreductase 
enzymes [14]. For these reasons, the question arises as to what degree the imaging characteristics of the 
two enantiomers of [18F]FMISO differ. In the field of nuclear medicine, this is particularly important, as 
the use of the more active enantiomer could potentially decrease the amount of administered 
radioactivity, and thus the dose to the patient. In addition, if one enantiomer is more specific, the use of 
this enantiomer could enhance image quality. Herein, we report an enantiospecific, single-step 
radiosynthesis of both enantiomers of [18F]FMISO. The biodistribution and imaging abilities of (S)-and 
(R)-[18F]FMISO were evaluated by PET in FaDu tumor xenograft bearing mice. 
 
2. Materials and methods 
2.1.  General 
Chemicals were purchased from Sigma-Aldrich and ABX GmbH and used without further purification 
unless stated otherwise. 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) was purified by sequential passing 
through silica, and activated alumina followed by vacuum distillation. Acetonitrile (ACN), ethyl acetate 
(EtOAc), and dichloromethane (DCM) were dried over 3 Å molecular sieves. All reactions were 
performed without exclusion of moisture and air. The silica cartridges (Supelco, 4 g) were pre-
conditioned with hexane.  The HPLC and radio-HPLC measurements were performed on a Hitachi 
EliteChrom equipped with Carrol & Ramsey 105-S radiodetector.  The normal phase chiral HPLC/radio-
HPLC was done with a Chiralpak AD-3, 150 × 2.1 mm column using hexane/i-PrOH (10:1) isocratic 
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elution. The GC was performed on a Shimadzu GC-2010 equipped with FactorFour calillary column, VF-
200 ms, 30 m, 0.32 mm. The aqueous solutions of [18F]fluoride were prepared by the 18O(p,n)18F 
reaction in a GE PETtrace cyclotron by irradiating 95% enriched [18O]water (2 mL) with the nominal 16.5 
MeV beam at 55 μA for 60–90 min. The decay corrected preparative radiochemical yields (RCYs) of both 
enantiomers of [18F]F-MISO were determined on the cartridge-purified sterile saline formulation of the 
product relative to [18F]fluoride. The radiochemical purity (RCP) was determined by radio-HPLC and 
calculated as: RCP=(Areaproduct/Total Area)*100%. 
 
2.2. Chemistry 
2.2.1. Starting materials and references 
The reference racemic FMISO was purchased from ABX GmbH. The reference enantiopure FMISO (both 
enantiomers) were prepared according to the reported procedure [15]. (R)- and (S)-2-nitro-1-(oxiran-2-
ylmethyl)-1H-imidazoles, the ((R) and (S)-MISO-epoxides) were synthesized similarly to the previously 
described protocol [16]: a stirred suspension of 2-nitroimidazole (1.00 g, 8.84 mmol, 1.0 eq) and cesium 
carbonate (145 mg, 0.44 mmol, 0.05 eq.) in dry ethanol (20 mL) was treated with the (R)- or the (S)-
epichlorohydrin (760 μL, 9.60 mmol, 1.1 eq.), and the resulting mixture was refluxed for 1 h under 
argon. The hot solution was filtered through glass wool; solids were washed with hot ethanol (10 mL). 
The reaction mixture was concentrated in vacuo and cooled to -20°C. The resulting off-white precipitate 
of 1-(2-hydroxy-3-chloropropyl)-2-nitroimidazole was dissolved in 20 mL of EtOAc and treated with 
aqueous NaOH (10% (w/v), 20 mL). After stirring for 1 h the organic layer was separated, dried over 
Na2SO4 giving after solvent removal 1.31g (88%) of (S)-MISO-epoxide or 1.26 g (85%) of (R)-MISO-
epoxide. 
 
2.2.2. Automated radiosynthesis, purification of (R)-and (S)-MISO, and quality control. 
[18F]HF(gas) was generated by addition of ~2 mL of proton-irradiated [18O]H2O containing  70-95 GBq of  
[18F]fluoride into a polyehtylene vial containing conc. H2SO4 (8 mL). Upon heating to 85˚C and 
ultrasound irradiation the gaseous [18F]HF was driven by argon flow into a receiving vial containing 3.5 
mg  of (-)tetramisol in 3 mL of t-AmOH. Upon completion of the [18F]HF  transfer (~30 min), 1.5 mL of the 
[18F]HF/(-)tetramisol mixture was transferred into a glass reaction vial containing a solution of 5 mg of 
(R)- or (S)-MISO-epoxides and 4.5 mg of (R,R)-Co(salen) ((N,N'-bis(3,5-di-tert-butylsalicylidene)-1,2-
cyclohexanediaminocobalt)) pre-oxidized in air in the presence of 250 µL of HFIP. The reaction mixture 
was heated at 65 oC for 15 min and then transferred onto a silica cartridge preconditioned with hexane. 
The product was purified by sequential elution with hexane (20 mL), DCM (20 mL) and then DCM/ACN 
(3:1, 20 mL). The organic solvent was removed under elevated temperature by applying vacuum 
(diaphragm pump) and a flow of Ar (40 mL/min). The dry product was dissolved in 3 mL of phosphate 
buffered saline (PBS, 3 mL) and filtered through a sterile filter, giving 628 MBq (RCY=2%) of the (R)-
[18F]FMISO and 2.97 GBq of (S)-[18F]FMISO (RCY=7%) at the end of the synthesis which took 2 hours. The 
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pH was measured using pH paper and the residual organic solvent test was performed using GC. The 
specific activity was estimated from a 5-point calibration curve using UV-VIS spectroscopy and found to 
exceed 100 GBq/μmol. 
 
2.2.3. Animals and cell lines 
All included animal experiments were approved by the Danish Animal Welfare Council, Ministry of 
Justice. Five week old female NMRI nude mice were purchased from Taconic Europe. Throughout the 
experiments the animals had ad libitum access to chow and water. After the mice arrived at the animal 
facility they were allowed to acclimatize for one week. Human pharyngeal squamous cell carcinoma 
(FaDu) cells, purchased from American Type Culture Collection (ATCC), were cultured in Minimum 
Essential Medium (MEM) with Earle’s salts and sodium bicarbonate supplemented with 2 mM L-
glutamine (both from Sigma-Aldrich), 1 mM sodium pyruvate, 1% MEM non-essential amino acids 
solution (100x), 10% fetal calf serum, 100 units/mL penicillin and 100 μg/mL streptomycin (all from 
Invitrogen) at 37 °C in 5% CO2. Tumors were established by subcutaneous injections of 10
6 cancer cells, 
dissolved in 100 μL of a (1:1) mixture of cell culture medium and Matrixgel™ (BD-Biosciences), into each 
flank. Tumors were allowed to grow for two weeks reaching a size of 100-280 mm3.    
 
2.2.4. PET imaging 
Animals were anesthetized by breathing 3% sevoflurane (Abbot Scandinavia) dissolved in a medical 
grade 35% oxygen/nitrogen gas mixture and the body temperature was kept stable by a heating pad. 
Mice with similar tumor sizes were evenly distributed between the two groups and had either (S)-
[18F]FMISO (4.7 ± 1.1 MBq (mean ± SD); n = 5) or (R)-[18F]FMISO (5.1 ± 0.5 MBq; n = 5) injected via the 
tail vein and were imaged at 1 h and 3 h p.i. using a microPET 120 (Siemens Medical Solutions). Ten 
minute static PET scans were acquired with an energy window of 350-650 keV and a time resolution of 6 
ns and stored in listmode. Additionally, a group of mice were dynamically PET scanned for two hours 
after intravenous injection of either (S)-[18F]FMISO (8.8 ± 1.8 MBq; n = 3) or (R)-[18F]FMISO (7.7 ± 1.4 
MBq; n = 3). The PET acquisition was initiated a few seconds before tracer administration. Subsequently 
after each PET scan, the animal bed was moved to a MicroCAT® II system (Siemens Medical Solutions) 
and all mice were CT scanned with an exposure time of 270 ms, a tube current of 500 μA and a tube 
voltage of 70 kVp.  
 
2.2.5. PET data analysis 
Listmode PET data was post-processed into 128 × 144 × 95 sinograms and reconstructed using the 
maximum a posteriori (MAP) algorithm 256 × 256 × 95 image matrices with a voxel size of 0.30 × 0.30 × 
0.80 and a resolution of 1.2 mm at the center field of view. Dynamic PET data was binned into 
timeframes of 20 × 3 s; 12 × 5 s; 6 × 30 s; 10 × 60 s; 7 × 900 s. CT scans were reconstructed into 512 × 
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512 × 768 image matrices with a voxel size of 0.09 × 0.09 × 0.09 using the Sheep-Logan algorithm. Image 
data were analyzed using Inveon software (Siemens Medical Solutions). PET and CT images were co-
registered and visually inspected. Regions of interest (ROIs) were manually created on tumors and 
sections of liver, heart, bladder, kidney and hind limb muscle tissue and the uptake quantified as percent 
of injected dose per gram (%ID/g). An average value from ROIs created on both left and right side on the 
animal was calculated for kidney and muscle uptake. Using the same setup time activity curves were 
generated from the dynamic datasets and the average uptake in the quantified tissue determined. 
Additionally, the tumor-to-muscle (T/M) and tumor-to-liver (T/L) ratios were calculated for all animals.        
 
.        
2.3. Statistical analysis 
All statistical analyses were performed in GraphPad Prism 6 (GraphPad Software). The uptake of (S)-
[18F]FMISO and (R)-[18F]FMISO was compared in different tissue using unpaired t-test with correction for 
multiple comparison using the Holm-Sidak method. Differences were considered significant at the 95% 
confidence level (p < 0.05). 
 
3. Results and discussion 
3.1. Automated radiosynthesis of (R)- and (S)-[18F]FMISO and quality control. 
To the best of our knowledge the only synthesis of both enantiopure FMISO antipodes was performed 
with fluorine-19 at natural abundance level [17]. Our approach to radiosynthesis of enantiopure (R)- and 
(S)-[18F]FMISO was based on a recently disclosed transition metal mediated enantioselective epoxide 
opening which utilized [18F]HF  in  a  combination  with  (-)tetramisole  and  (R,R)-Co(salen) [18]. To 
maximize the enantiomeric purity of the desired (R)- and (S)-[18F]FMISO the radiosynthesis was 
performed on enantiopure substrates. Due to a notable cooperative effect [15] the stereochemically 
matched enantiomers of Co(salen) were used (Scheme 1): 
 
The radiosynthesis was automated using a custom-made automatic synthesizer controlled by LabView 
software (Fig. 2). 
 
The [18F]HF generator described by us earlier [19,20] was  integrated within the automatic 
radiosynthesis platform (Fig.2 , top).  After [18F]HF  transfer the [18F]HF/(-)tetramisol mixture was 
transferred into the reaction vial containing a solution of (R)- or (S)-MISO-epoxides and (R,R)- or (S,S)-
Co(salen) (Fig.2, bottom). After reaction, the reaction mixture was transferred onto a silica cartridge and 
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the product was purified by gradient elution. The organic solvent was removed and the dry product 
collected in the product vial was dissolved in PBS and filtered through a sterile filter.  
 
The final formulation of  (R)- and (S)- [18F]FMISO passed the pH test (pH=7.0-7.5). The residual organic 
solvents (ACN and DCM) were below the limit of detection. The identity of the synthesized [18F]FMISO 
was confirmed by radio-HPLC and HPLC against the reference sample purchased from ABX GmbH. The 
HPLC analysis revealed no significant absorption at 254 nm, and radio-HPLC showed that the 
radiochemical and enantiomeric purities of the (R)- and the (S)- enantiomers of [18F]FMISO were higher 
than 99% (Fig. 3).  
 
3.2. PET evaluation of (R)- and (S)-[18F]FMISO 
Fig. 4 shows representative transverse PET images of mice bearing FaDu tumor xenografts acquired 1 
and 3 hours after injection of (R)- and (S)-[18F]FMISO.  
 
Table 1 shows the PET-derived tissue uptake in different organs. Both enantiomers showed pronounced 
abdominal distribution dominated by renal and, to a lesser degree, hepatobiliary clearance. There was 
no visual variation in the contrast between the PET images acquired within the two groups. The uptake 
of (R)- and  (S)-[18F]FMISO in the liver, heart, kidney, bladder and muscle tissue were the same, within 
the error of experiment, both 1 and 3 hours p.i. Importantly, there was no significant difference in the 
tumor accumulation between the two groups. Generally, the tumor uptake was between 2.0-2.5 %ID/g 
1 hour p.i. decreasing to 1.0-1.5 %ID/g 3 hours p.i. This also resulted in compatible T/M-ratio with (R)- 
and (S)-[18F]FMISO increasing from 1.6 ± 0.2 and 1.4 ± 0.3 1 hour p.i. to 3.7 ± 0.7 and 3.6 ± 1.3 3 hours 
p.i., respectively. In addition, no significant difference was seen in the T/L-ratio both 1 and 3 hours p.i. 
(Figure 5). 
 
A somewhat different picture emerged from the 2 hours dynamic PET imaging (Fig. 6). When the mean 
time activity curves from the two enantiomers were compared, a faster uptake of the (R)-form was 
observed in tumor tissue. The difference got progressively smaller with time. However, a similar trend 
was seen in muscle and liver tissue and no difference was observed between the mean T/M- and T/L- 
ratios of (S)-[18F]FMISO and (R)-[18F]FMISO during the 2 hours dynamic scan. The nature of the higher 
initial affinity of the (R)-isomer is unclear at the moment. 
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4. Conclusion 
In conclusion, the individual enantiopure (R)- and (S)-enantiomers of [18F]FMISO were synthesized using 
a novel approach based on Co(salen) mediated epoxide opening with [18F]HF. The PET imaging 
characteristics of the (R)- and (S)-forms were compared in mice bearing subcutaneous FaDu tumor 
xenografts.  Although the (R)-enantiomer of [18F]FMISO demonstrated a somewhat faster initial tumor, 
liver and muscle uptake the T/M- and T/L ratios for the (R)- and (S)-forms were the same at all times. 
Image-derived biodistribution showed no significant differences in tissue uptake for the (R)- and (S)-
forms 1 and 3 hours after administration. On the basis of these studies we can conclude that the use of 
enantiopure [18F]FMISO presents no practical clinical benefits for PET imaging. 
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Scheme 1. Radiosynthesis of (R)- and (S)- enantiomers of [18F]FMISO. 
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Fig. 1. Racemic [18F]FMISO. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
Fig. 2. Automated module for Co(salen)-mediated radiosynthesis of (R)-and (S)- enantiomers of 
[18F]FMISO using [18F]HF/(-)tetramisol. 
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Fig. 3. Chiral radio-HPLC (top, red, arbitrary units) traces of the final formulation of (R)- and (S)-
[18F]FMISO, and HPLC (DAD 254 nm) trace of a racemic commercial reference of [18F]FMISO obtained 
from ABX GmbH. 
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Fig. 4. Representative transverse images obtained from 10 min static PET scans of tumor-bearing mice 
acquired 1 h (left) and 3 h (right) after administration of (R)-[18F]FMISO (5.17 MBq; top lane) and (S)-
[18F]FMISO (4.38 MBq; bottom lane). White arrows indicate tumors. 
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Fig. 5. Tumor-to-muscle and tumor-to-liver ratio (mean ± SEM) from PET images of mice with FaDu 
tumor xenografts PET scanned 1 h and 3 h p.i. of (R)-[18F]FMISO (5.1 ± 0.5 MBq (mean ± SEM); n = 5) or 
(S)-[18F]FMISO (4.7 ±1.1 MBq; n = 5). During PET scans mice were 
anesthetized by breathing 3% of sevoflurane dissolved in a gas mixture of 35% oxygen in nitrogen No 
significant differences in T/M- or T/L -ratios were found between the enantiomers at any time point (p < 
0.05). 
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Fig. 6. Time activity curves from tumor-bearing mice obtained from 2 h dynamic PET scans showing the 
accumulation (mean ± SD) of radioactivity over time in (A) tumor, (B) liver, (C) muscle, and (D) kidney; as 
well as (E) tumor-to-liver ratio and (F) tumor-to-muscle ratio. The PET acquisition was started a few 
seconds before intravenous injection of either (R)-[18F]FMISO (7.7 ± 1.4 MBq (mean ± SD); n = 3) or (S)-
[18F]FMISO (8.8 ±1.8 MBq; n =3). All animals were anesthetized during the scan by breathing 3% of 
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sevoflurane dissolved in a gas mixture of 35% oxygen in nitrogen. Except for tumor-to-muscle and 
tumor-to-liver ratios, results are expressed as %ID/g. 
